ADVERTISEMENT

Conference Report

AIDS 2022 — Rapid and consistent viral load suppression with dolutegravir

Shrabasti Bhattacharya   |   04 August 2022

Takeaway

  • The majority of children and adolescents living with HIV in the real world achieved rapid viral load suppression (VLS) with dolutegravir, with improvements maintained for up to 2-3 years.

Why this matters

  • Dolutegravir-based antiretroviral therapy (ART) has been a preferred treatment regimen for children and adolescents living with HIV.
  • Recent...

          

November Challenge

Ends in 1d 7h
left
right

Topic Challenges

left
right